Adverum Biotechnologies, Inc. clinical trials
Acquired by Eli Lilly and Company, Dec 9, 2025 · source ↗
The registry lists 11 studies whose lead sponsor is Adverum Biotechnologies, Inc. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 27, 2026.
- 11studies on the registry
- 2open to participants now
- 2phase 3 studies under way
- 2reach primary completion within a year
Before and after it joined Eli Lilly and Company
- First submitted before Adverum Biotechnologies, Inc. became part of Eli Lilly and Company
- 9
- First submitted after Adverum Biotechnologies, Inc. became part of Eli Lilly and Company
- 2
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Coming up
2 of Adverum Biotechnologies, Inc.’s studies under way reach primary completion within a year, all of them phase 3. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- 1DDec
- JJan ’27’27
- FFeb
- MMar
- AApr
- MMay
- JJun
- JJul
- AAug
- SSep
- OOct
- 1NNov
All 2
- Dec 2026Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular DegenerationPhase 3 · NCT06856577
- Nov 2027Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)Phase 3 · NCT07482176
Add all 2 to your calendar (.ics) → With an account.
All 11 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 16
- 17
- 218
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 226
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Adverum Biotechnologies, Inc.11 studies
Something wrong with this grouping? Tell us on the Eli Lilly and Company page.
Studies
Recruiting first, then most recently updated. Showing 11 of 11. All Eli Lilly and Company studies →
- Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)RecruitingNCT07482176Phase 3
Sponsor listed in the registry: Adverum Biotechnologies, Inc. · First submitted after Adverum Biotechnologies, Inc. became part of Eli Lilly and Company
- Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular DegenerationRecruitingNCT07630649Phase 2
Sponsor listed in the registry: Adverum Biotechnologies, Inc. · First submitted after Adverum Biotechnologies, Inc. became part of Eli Lilly and Company
- Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]Active, not recruitingNCT05536973Phase 2
Sponsor listed in the registry: Adverum Biotechnologies, Inc. · First submitted before Adverum Biotechnologies, Inc. became part of Eli Lilly and Company
- Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)Active, not recruitingNCT05607810
Sponsor listed in the registry: Adverum Biotechnologies, Inc. · First submitted before Adverum Biotechnologies, Inc. became part of Eli Lilly and Company
- Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular DegenerationActive, not recruitingNCT06856577Phase 3
Sponsor listed in the registry: Adverum Biotechnologies, Inc. · First submitted before Adverum Biotechnologies, Inc. became part of Eli Lilly and Company
- Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]Active, not recruitingNCT04645212
Sponsor listed in the registry: Adverum Biotechnologies, Inc. · First submitted before Adverum Biotechnologies, Inc. became part of Eli Lilly and Company
- ADVM-022 Intravitreal Gene Therapy for DMECompletedNCT04418427Phase 2
Sponsor listed in the registry: Adverum Biotechnologies, Inc. · First submitted before Adverum Biotechnologies, Inc. became part of Eli Lilly and Company
- Long-Term Follow-up Study of ADVM-043CompletedNCT03804021
Sponsor listed in the registry: Adverum Biotechnologies, Inc. · First submitted before Adverum Biotechnologies, Inc. became part of Eli Lilly and Company
- Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) DeficiencyCompletedNCT02168686Phase 1/2
Sponsor listed in the registry: Adverum Biotechnologies, Inc. · First submitted before Adverum Biotechnologies, Inc. became part of Eli Lilly and Company
- ADVM-022 Intravitreal Gene Therapy for Wet AMDCompletedNCT03748784Phase 1
Sponsor listed in the registry: Adverum Biotechnologies, Inc. · First submitted before Adverum Biotechnologies, Inc. became part of Eli Lilly and Company
- A Study to Characterize the Cardiac Phenotype of Individuals With Friedreich's Ataxia (CARFA Study)CompletedNCT02840669Not applicable
Sponsor listed in the registry: Adverum Biotechnologies, Inc. · First submitted before Adverum Biotechnologies, Inc. became part of Eli Lilly and Company